LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Inclusion Criteria: * Female subjects with regular menstrual cycles (postmenarcheal for at least two years and premenopausal) aged 14 to 45 years. * Female subjects aged between 14 to 17 years (inclusive) will only be included provided that: * Applicable national, state, and local laws allow subjects in this age group to consent/assent to receive contraceptive services, and * All applicable laws and regulations regarding the informed consent/assent of the subjects to participate in clinical trials are observed. * Systolic blood pressure \< 140 mmHg, diastolic blood pressure \< 90 mmHg at Visit 1, in sitting position after 5 minutes of rest. * Menstruation restarted for at least 6 months since last pregnancy (only applicable for women that were pregnant). * Be able and willing to provide written informed consent, or assent if the subject is an adolescent, prior to undergoing any trial-related procedures. * Willing to use trial contraception for thirteen 28-day cycles (hormonal treatment arm) or to use non-hormonal contraceptive methods for the duration of the trial (non-hormonal contraceptive arm), respectively. Exclusion Criteria: * Contraindications to the use of LF111 or DRSP 3.5 mg chewable tablets (such as active arterial or venous thromboembolic disorders, liver tumors benign or malignant, hepatic impairment, renal impairment, adrenal insufficiency, presence or history of cervical cancer or progestin-sensitive cancers, known or suspected sex-steroid sensitive mal…